G1 Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

G1 Therapeutics

31/07/2023 19:33

* G1 Therapeutics Inc  GTHX.OQ   GTHX.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 2. 
    * The Research Triangle Park North Carolina-based  company
is
expected to report  a 173.3% increase in revenue to $28.9
million from $10.57 million a year ago, according to the mean
estimate from 8 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for G1 Therapeutics Inc
is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $9.5​, above​ its last closing price of $2.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.62       -0.64      -0.53     Beat    17.2
 Dec. 31 2023  -0.84       -0.84      -0.73     Beat    13.5
 Sep. 30 2022  -0.61       -0.63      -0.59     Beat    6.7​
 Jun. 30 2022  -1.02       -1.02      -0.92     Beat    9.7
 ​​Mar.        -0.97       -0.97      -1.15     Missed  -18
 31 2022                                                
 Dec. 31 2021  -1.03       -1.03      -0.94     Beat    9.2​
 Sep. 30 2021  -1.01       -1.01      -1.00     Beat    0.5
 Jun. 30 2021  -0.97       -0.97      -0.94     Beat    3.4
 This summary was machine generated July 31 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated